Board of Directors

PC hi-res version 1173k
Version 2 (JPG) 925k
Version 3 (JPG) 401k
Version 4 (JPG) 461k

Andrew Witty was named CEO designate for GSK in October 2007 and assumed the position of Chief Executive Officer on 21 May 2008. He is a member of the Board and Corporate Executive Team and previously held the role of President, Pharmaceuticals Europe, for five years.

Andrew joined Glaxo in 1985 and held a variety of roles in the UK business. He was a Sales Representative for the Respiratory business, held a variety of Marketing roles and was Director of Pharmacy and Distribution.

He has worked in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields and has been involved in multiple new product development programmes.

In 1993, Andrew was appointed Managing Director of Glaxo South Africa and later Area Director for GlaxoWellcome, South and East Africa. Subsequently he moved to North Carolina as Vice President and General Manager, Marketing for GlaxoWellcome Inc., the group’s US subsidiary.

Andrew then moved to Singapore and led the Group’s operations in Asia as Senior Vice President, Asia Pacific prior to his appointment to the Corporate Executive Team as President of GSK Europe in 2003.

While in Singapore Andrew was a Board Member of the Singapore Economic Development Board, the Singapore Land Authority and in 2003 was awarded the Public Service Medal by the Government of Singapore.

Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK.

Andrew is currently a Non-Executive Director of the UK’s Office for Strategic Co-ordination of Health Research, sits on the Imperial College Commercialisation Advisory Board, is a member of the Health Innovation Council and is a member of INSEAD UK Council.

Andrew has a Joint Honours BA in Economics from the University of Nottingham.